Cargando…

Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cancer

BACKGROUND: The dismal prognosis of patients diagnosed with pancreatic cancer points to our limited arsenal of effective anticancer therapies. Oncogenic K-RAS hyperactivation is virtually universal in pancreatic cancer, that confers drug resistance, drives aggressive tumorigenesis and rapid metastas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, R, Smyrk, T C, Reed, N R, Schmidt, R L, Schnelldorfer, T, Chari, S T, Petersen, G M, Tang, A H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453663/ https://www.ncbi.nlm.nih.gov/pubmed/25584484 http://dx.doi.org/10.1038/bjc.2014.659

Ejemplares similares

H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 bladder carcinoma cells
por: Li, C, et al.
Publicado: (2005)

Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels
por: Smalley, K S M, et al.
Publicado: (2007)

Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicine
por: Smith, G, et al.
Publicado: (2010)

Prostate cancer cell malignancy via modulation of HIF-1α pathway with isoflurane and propofol alone and in combination
por: Huang, H, et al.
Publicado: (2014)

Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells
por: Roberts, D L, et al.
Publicado: (2009)

Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma: the oncogenic role of the ligands
por: Almazán-Moga, A, et al.
Publicado: (2017)

The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function
por: Baker, L C J, et al.
Publicado: (2012)

Inhibitory effect of a TGFβ receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells
por: Shinto, O, et al.
Publicado: (2010)

Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells
por: Carbajo-Pescador, S, et al.
Publicado: (2013)

Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy
por: Harada, H, et al.
Publicado: (2009)

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
por: Rowland, A, et al.
Publicado: (2015)

Impaired TNFα-induced A20 expression in E1A/Ras-transformed cells
por: Huang, H-L, et al.
Publicado: (2009)

Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells
por: Mancini, M, et al.
Publicado: (2014)

A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: a proof of principle
por: Swanson, K R, et al.
Publicado: (2008)

MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases
por: Nagy, E, et al.
Publicado: (2014)

Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa
por: de Bruijn, M T, et al.
Publicado: (2010)

Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment
por: Takagi, K, et al.
Publicado: (2013)

Epigenetic silencing of miRNA-9 is associated with HES1 oncogenic activity and poor prognosis of medulloblastoma
por: Fiaschetti, G, et al.
Publicado: (2014)

Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways
por: Zhang, Hao, et al.
Publicado: (2016)

HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer
por: Abdel-Fatah, T M A, et al.
Publicado: (2014)

Differential pattern of HIF-1α expression in HNSCC cancer stem cells after carbon ion or photon irradiation: one molecular explanation of the oxygen effect
por: Wozny, Anne-Sophie, et al.
Publicado: (2017)

HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma
por: Liu, Y J, et al.
Publicado: (2014)

Rapid non-genomic signalling by 17β-oestradiol through c-Src involves mTOR-dependent expression of HIF-1α in breast cancer cells
por: Sudhagar, S, et al.
Publicado: (2011)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer
por: Crozier, J E M, et al.
Publicado: (2006)

Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection
por: Fu, Yi-Peng, et al.
Publicado: (2016)

Macrophages promote angiogenesis in human breast tumour spheroids in vivo
por: Bingle, L, et al.
Publicado: (2006)

Expression and clinicopathological correlation of Ki-67 in gallbladder carcinoma
por: Gupta, Amit, et al.
Publicado: (2021)

Association of Ki-67 With Clinicopathological Factors in Breast Cancer
por: ., Nishit, et al.
Publicado: (2021)

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity
por: Meulendijks, Didier, et al.
Publicado: (2017)

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
por: Nakayama, N, et al.
Publicado: (2008)

Establishment and molecular characterisation of seven novel soft-tissue sarcoma cell lines
por: Salawu, Abdulazeez, et al.
Publicado: (2016)

Kinase-driven metabolic signalling as a predictor of response to carboplatin–paclitaxel adjuvant treatment in advanced ovarian cancers
por: Sereni, Maria Isabella, et al.
Publicado: (2017)

Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations
por: Bramley, M, et al.
Publicado: (2006)

Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer
por: Seo, An Na, et al.
Publicado: (2016)

Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer
por: Sun, S, et al.
Publicado: (2015)

Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction
por: Lickliter, J D, et al.
Publicado: (2007)

Class III β-tubulin expression and in vitro resistance to microtubule targeting agents
por: Stengel, C, et al.
Publicado: (2010)

In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol
por: Chander, S K, et al.
Publicado: (2007)

2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer
por: Tagg, S L C, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_c0v8mqfpkc79iuum5u8147q4ns